Curriculum
Module 12 · 65 min

Cell Death Pathways

Apoptosis, necroptosis, pyroptosis, ferroptosis — and why the difference matters clinically.

CoreClinicalResearch
Topics

What this module covers

  • 01Apoptosis: intrinsic (mitochondrial) and extrinsic (death-receptor) pathways
  • 02Bcl-2 family: BH3-only sensors, multi-domain effectors (BAX/BAK), guardians (Bcl-2/xL/Mcl-1)
  • 03Caspase cascade and apoptotic body clearance
  • 04Necroptosis: RIPK1/RIPK3/MLKL
  • 05Pyroptosis: inflammasome → caspase-1 → gasdermin D pore
  • 06Ferroptosis: GPX4, lipid peroxidation, iron
  • 07Immunogenic vs tolerogenic cell death
Deep dives

Lesson sub-pages

Learning objectives

By the end of this module you will be able to

  • L01Distinguish death modalities by morphology, mediators, and immunological consequence.
  • L02Explain how venetoclax (BCL-2 inhibitor) achieves selective tumour killing.
  • L03Discuss when cell death is therapeutic, pathologic, or both.
Expected takeaways

What you should walk away believing

  • Apoptosis is silent; necroptosis, pyroptosis and ferroptosis are inflammatory.
  • Cancers up-regulate Bcl-2 family guardians; BH3-mimetics tip the balance to death.
  • Ferroptosis is a major emerging axis in neurodegeneration, ischaemia-reperfusion, and resistant cancer.
Core summary

At the Core level

Cells die in regulated ways — and the way they die matters because each mode produces different signals to the immune system. Apoptotic cells are silently cleared by efferocytosis; pyroptotic and necroptotic cells release DAMPs and inflame the tissue. Therapeutics now both induce death (oncology) and block it (neurodegeneration trials).

Myth vs reality

Common misconception

Claim

Apoptosis and necrosis are the only two ways cells die.

Reality

At least a dozen regulated death modalities are now recognised (necroptosis, pyroptosis, ferroptosis, NETosis, cuproptosis, parthanatos, entosis, lysosomal cell death).

Evidence-graded claims

Claims, scored A–F

A
Venetoclax + azacitidine improves AML survival in older adults
VIALE-A confirmed; standard of care.
F
Caspase inhibition improves sepsis survival
Trials negative; redundant death pathways take over.
C
Ferroptosis induction will be a major oncology modality
Promising preclinical; clinical proof-of-concept pending.
Quiz

Check your understanding

Q1. Pyroptosis effector pore is formed by:
Q2. Venetoclax targets:
Flashcards

Lock it in

1 / 3
Front
Two arms of intrinsic apoptosis sensors?
Click to flip
Suggested reading

Primary literature